---
title: "Cytisinicline in Smoking cessation: Clinical evidence"
description: "Formulary evidence on Cytisinicline in Smoking cessation: Clinical evidence. Covers ORCA-2, ORCA-3, ORCA-OL, ORCA-1, ORCA-V1, ISRCTN37568749, and 20 further headings. 251 evidence topics quoted from 39 sources."
canonical: "https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Cytisinicline in Smoking cessation: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 ORCA-2

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Efficacy and safety objective

> “efficacy and safety”

Source: [Achieve Life Sciences (2022)](https://ir.achievelifesciences.com/news-events/press-releases/detail/141/achieve-life-sciences-announces-successful-statistically-significant-smoking-cessation-results-in-phase-3-orca-2-clinical-trial-of-cytisinicline-in-adult-smokers)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### U.S. trial dates and site count

| Characteristic | Quoted value |
| --- | --- |
| Sites | “17” |
| Start month | “October 2020” |
| End month | “December 2021” |

Source: [Rigotti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10336611/)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Randomization, treatment duration, and sample

> “3mg cytisinicline dosed 3 times daily for a period of 6-weeks or 12-weeks compared to placebo in 810 adult smokers (randomized 1:1:1).”

Source: [Achieve Life Sciences (2022)](https://ir.achievelifesciences.com/news-events/press-releases/detail/141/achieve-life-sciences-announces-successful-statistically-significant-smoking-cessation-results-in-phase-3-orca-2-clinical-trial-of-cytisinicline-in-adult-smokers)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Smoking eligibility threshold

| Characteristic | Quoted value |
| --- | --- |
| Minimum cigarettes per day | “10” |

Source: [Rigotti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10336611/)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Cytisinicline dose and schedules

> “3mg cytisinicline dosed three times daily for 6 and 12 weeks compared to placebo.”

Source: [Achieve Life Sciences ORCA-2](https://achievelifesciences.com/products/phase-3-orca-2-trial/)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Continuous Smoking Abstinence as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary abstinence endpoint

| Characteristic | Quoted value |
| --- | --- |
| Verification method | “biochemically verified” |
| Primary assessment period | “last 4 weeks of treatment” |

Source: [Achieve Life Sciences (2022)](https://ir.achievelifesciences.com/news-events/press-releases/detail/141/achieve-life-sciences-announces-successful-statistically-significant-smoking-cessation-results-in-phase-3-orca-2-clinical-trial-of-cytisinicline-in-adult-smokers)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Sample size and power

| Characteristic | Quoted value |
| --- | --- |
| Planned participants | “750” |
| Planned power | “96%” |
| Randomized participants | “810” |
| Safety population | “809” |

Source: [Rigotti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10336611/)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Primary analysis population and multiplicity

| Characteristic | Quoted value |
| --- | --- |
| Analysis of all randomized participants: multiplicity adjustment | “Hochberg procedure” |

Source: [Rigotti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10336611/)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Trial completion

| Characteristic | Quoted value |
| --- | --- |
| Participants completing follow-up | “618 (76.3%)” |

Source: [Rigotti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10336611/)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Baseline characteristics

| Characteristic | Quoted value |
| --- | --- |
| Mean age, years | “52.5” |
| Female participants | “54.6%” |
| Mean cigarettes per day | “19.4” |

Source: [Rigotti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10336611/)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Biochemically confirmed continuous smoking abstinence

| Treatment duration | Assessment            | Cytisinicline | Placebo | Odds ratio (95% CI) | P value |
| ------------------ | --------------------- | ------------: | ------: | ------------------- | ------: |
| 6 weeks            | Weeks 3–6, primary    |       “25.3%” |  “4.4%” | “8.0 (3.9-16.3)”    | “<.001” |
| 12 weeks           | Weeks 9–12, primary   |       “32.6%” |  “7.0%” | “6.3 (3.7-11.6)”    | “<.001” |
| 6 weeks            | Weeks 3–24, secondary |        “8.9%” |  “2.6%” | “3.7 (1.5-10.2)”    |  “.002” |
| 12 weeks           | Weeks 9–24, secondary |       “21.1%” |  “4.8%” | “5.3 (2.8-11.1)”    | “<.001” |

Source: [Rigotti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10336611/)

<a id="topic-3.1.1.8.3-2"></a>

###### Sponsor-reported pooled COPD subgroup findings

> “statistically significant increases in continuous smoking abstinence compared to placebo for both COPD and non-COPD subgroups.”

Source: [Achieve Life Sciences Thorax publication announcement (2025)](https://achievelifesciences.com/achieve-announces-thorax-publication-of-cytisiniclines-potential-efficacy-and-tollerability-for-smoking-cessation-in-individuals-with-copd/)

<a id="topic-3.1.1.8.3-3"></a>

###### Number needed to treat at 24 weeks

> “At 24 weeks, this new regimen produced 1 additional person abstinent for every 6 people treated with cytisinicline for 12 weeks or for every 11 people treated for 6 weeks”
> “Participants in the cytisinicline groups had 6- to 8-fold higher odds of continuous smoking abstinence at the end of treatment than participants receiving placebo plus behavioral support.”
> “The efficacy of cytisinicline treatment for both 6 and 12 weeks, compared with placebo, was sustained to 24-week follow-up and was consistently demonstrated in subgroups defined by baseline characteristics.”

Source: [Rigotti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10336611/)

Additional sources: [Prochaska et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40962497/); [Rigotti et al. (2026a)](https://achievelifesciences.com/wp-content/uploads/2026/03/ALS28399-SRNT-2026_Oral_Prior-treatment_v2.11_3Mar26.pdf); [Dizon et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.e22676)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### Cigarette craving on the Brief Questionnaire of Smoking Urges

> “To assess cigarette craving between groups, the Brief Questionnaire of Smoking Urges (QSU-brief) was administered at clinic visits on day 0 and at weeks 1 to 6.”
> “The mean total cigarette craving score, using the QSU-brief, declined more rapidly between baseline and week 6 among participants who received cytisinicline for 6 or 12 weeks compared with placebo”
> “Confidence intervals for the effect estimates at weeks 1 to 6 excluded 0, providing evidence of a rapid and sustained effect.”

Source: [Rigotti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10336611/)

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Treatment-related serious adverse events

> “no treatment-related serious adverse events reported.”

Source: [Achieve Life Sciences (2022)](https://ir.achievelifesciences.com/news-events/press-releases/detail/141/achieve-life-sciences-announces-successful-statistically-significant-smoking-cessation-results-in-phase-3-orca-2-clinical-trial-of-cytisinicline-in-adult-smokers)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

The comparator was placebo rather than another cessation medication. The primary endpoint assessed abstinence near the end of treatment; follow-up extended to week 24. The trial therefore does not establish comparative effectiveness against active medication or durability beyond 24 weeks.

Source: [Rigotti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10336611/)

<a id="heading-3.1.2"></a>

#### 3.1.2 ORCA-3

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Efficacy and safety objective

> “efficacy and safety”

Source: [Achieve Life Sciences ORCA-3](https://achievelifesciences.com/products/phase-3-orca-3-trial/)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Trial population and U.S. sites

> “ORCA-3 randomized 792 adult smokers at 20 clinical trial sites in the United States.”

Source: [Achieve Life Sciences ORCA-3](https://achievelifesciences.com/products/phase-3-orca-3-trial/)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Randomized trial design

> “3-group, double-blind, randomized placebo-controlled clinical trial”

Source: [Rigotti et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12012700/)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Smoking eligibility threshold

| Characteristic | Quoted value |
| --- | --- |
| Minimum cigarettes smoked daily | “10” |

Source: [Rigotti et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12012700/)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Dose and treatment duration

> “3mg cytisinicline dosed 3 times daily for a period of 6 weeks or 12 weeks”

Source: [Achieve Life Sciences ORCA-3](https://achievelifesciences.com/products/phase-3-orca-3-trial/)

<a id="topic-3.1.2.5-2"></a>

###### Concomitant behavioral intervention

> “standard behavioral support for the duration of the trial.”

Source: [Achieve Life Sciences ORCA-3](https://achievelifesciences.com/products/phase-3-orca-3-trial/)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Continuous Smoking Abstinence as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Biochemical verification of abstinence

> “biochemically-verified continuous smoking abstinence”

Source: [Achieve Life Sciences ORCA-3](https://achievelifesciences.com/products/phase-3-orca-3-trial/)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Sample size and statistical power

| Characteristic | Quoted value |
| --- | --- |
| Planned participants | “750” |
| Power | “96%” |
| Randomized participants | “792” |
| Safety-analysis participants | “785” |

Source: [Rigotti et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12012700/)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Primary analysis and multiplicity

| Characteristic | Quoted value |
| --- | --- |
| Efficacy analysis principle | “intent-to-treat” |
| Multiplicity procedure | “Hochberg procedure” |
| Classification of missed assessments | “still smoking” |

Source: [Rigotti et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12012700/)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Completion at week 24

| Characteristic | Quoted value |
| --- | --- |
| Participants completing the trial | “628” |
| Completion percentage | “79.3%” |

Source: [Rigotti et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12012700/)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Baseline age and sex

| Characteristic | Quoted value |
| --- | --- |
| Mean age, years | “52.0” |
| Female participants | “55.4%” |

Source: [Rigotti et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12012700/)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Biochemically confirmed smoking cessation

| Treatment duration | Assessment            | Cytisinicline | Placebo | Odds ratio (95% CI) | P value |
| ------------------ | --------------------- | ------------: | ------: | ------------------- | ------: |
| 6 weeks            | Weeks 3–6, primary    |       “14.8%” |  “6.0%” | “2.9 (1.5-5.6)”     | “<.001” |
| 12 weeks           | Weeks 9–12, primary   |       “30.3%” |  “9.4%” | “4.4 (2.6-7.3)”     | “<.001” |
| 6 weeks            | Weeks 3–24, secondary |        “6.8%” |  “1.1%” | “6.3 (1.9-34.6)”    | “<.001” |
| 12 weeks           | Weeks 9–24, secondary |       “20.5%” |  “4.2%” | “5.8 (2.9-12.5)”    | “<.001” |

Source: [Rigotti et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12012700/)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### Change in smoking-urge score at week 6

| Characteristic | Quoted value |
| --- | --- |
| Cytisinicline, mean change in points | “−15.2” |
| Placebo, mean change in points | “−12.0” |

Source: [Rigotti et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12012700/)

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Adverse events: placebo, 6-week cytisinicline, 12-week cytisinicline

> “Insomnia: (7.6%, 11.0%, 11.9%)”
> “Abnormal dreams: (5.7%, 9.1%, 7.7%)”
> “Nausea (7.3%, 9.5%, 6.9%)”
> “Headache (6.1%, 7.6%, 8.5%)”
> “no treatment-related serious adverse events reported.”

Source: [Achieve Life Sciences (2023)](https://ir.achievelifesciences.com/sec-filings/all-sec-filings/content/0000950170-23-023533/0000950170-23-023533.pdf)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

The study replicated placebo-controlled findings but did not compare cytisinicline with an active cessation medication. Of 792 randomized participants, 628 completed the trial. Follow-up through week 24 does not establish longer-term abstinence or safety.

Source: [Rigotti et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12012700/)

<a id="heading-3.1.3"></a>

#### 3.1.3 ORCA-OL

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Extended exposure objective

> “long-term safety”

Source: [Rigotti et al. (2026c)](https://achievelifesciences.com/wp-content/uploads/2026/05/ATS_2026_ORCA-OL.pdf)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### U.S. study sites

| Characteristic | Quoted value |
| --- | --- |
| Number of U.S. sites | “29” |

Source: [Rigotti et al. (2026c)](https://achievelifesciences.com/wp-content/uploads/2026/05/ATS_2026_ORCA-OL.pdf)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Open-label exposure-safety study

> “The ORCA-OL trial, an open-label, long-term, exposure safety study, enrolled 475 adults who smoke cigarettes, use e-cigarettes, or both.”

Source: [Achieve Life Sciences 52-week safety data announcement (2026)](https://ir.achievelifesciences.com/news-events/press-releases/detail/262/achieve-life-sciences-presents-safety-data-from-52-weeks-of-continuous-cytisinicline-treatment)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Prior-study eligibility

> “ORCA-2, ORCA-3, or ORCA-V1”

Source: [Rigotti et al. (2026c)](https://achievelifesciences.com/wp-content/uploads/2026/05/ATS_2026_ORCA-OL.pdf)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Continuous treatment regimen

> “cytisinicline 3 mg three times daily for up to 52 weeks of continuous exposure”

Source: [Achieve Life Sciences 52-week safety data announcement (2026)](https://ir.achievelifesciences.com/news-events/press-releases/detail/262/achieve-life-sciences-presents-safety-data-from-52-weeks-of-continuous-cytisinicline-treatment)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Safety Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Safety assessment

> “Treatment-emergent adverse event (TEAE) incidence”

Source: [Rigotti et al. (2026c)](https://achievelifesciences.com/wp-content/uploads/2026/05/ATS_2026_ORCA-OL.pdf)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Treated participants

| Characteristic | Quoted value |
| --- | --- |
| Treated sample | “475” |

Source: [Rigotti et al. (2026c)](https://achievelifesciences.com/wp-content/uploads/2026/05/ATS_2026_ORCA-OL.pdf)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Safety analysis set

> “treated population”

Source: [Rigotti et al. (2026c)](https://achievelifesciences.com/wp-content/uploads/2026/05/ATS_2026_ORCA-OL.pdf)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Exposure duration

| Characteristic | Quoted value |
| --- | --- |
| Participants exposed for at least 24 weeks, number and percentage | “392 (82.5)” |
| Participants exposed for at least 48 weeks, number and percentage | “319 (67.2)” |
| Participants exposed for at least 51 weeks, number and percentage | “281 (59.2)” |

Source: [Rigotti et al. (2026c)](https://achievelifesciences.com/wp-content/uploads/2026/05/ATS_2026_ORCA-OL.pdf)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Baseline age and sex

| Characteristic | Quoted value |
| --- | --- |
| Median age, years | “55” |
| Female participants, number and percentage | “275 (57.9)” |

Source: [Rigotti et al. (2026c)](https://achievelifesciences.com/wp-content/uploads/2026/05/ATS_2026_ORCA-OL.pdf)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

Not applicable.

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

###### Exit-survey design

> “voluntary post-trial survey”

Source: [Achieve Life Sciences SRNT ORCA-OL data announcement (2026)](https://achievelifesciences.com/achieve-presents-orca-ol-data-at-srnt/)

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Serious adverse events, deaths, and discontinuations

> “Serious TEAEs occurred in 31 participants (6.5%)”
> “Two deaths (0.4%) occurred and were considered unrelated to treatment”
> “few participants (5.7%) discontinued due to TEAEs”

Source: [Rigotti et al. (2026c)](https://achievelifesciences.com/wp-content/uploads/2026/05/ATS_2026_ORCA-OL.pdf)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

This open-label study had no concurrent comparator. It enrolled participants previously treated in the ORCA program, rather than a newly recruited randomized population. Exposure declined from 475 treated participants to 281 with at least 51 weeks of treatment. The exit survey was voluntary.

Source: [Achieve Life Sciences 52-week safety data announcement (2026)](https://ir.achievelifesciences.com/news-events/press-releases/detail/262/achieve-life-sciences-presents-safety-data-from-52-weeks-of-continuous-cytisinicline-treatment); [Rigotti et al. (2026c)](https://achievelifesciences.com/wp-content/uploads/2026/05/ATS_2026_ORCA-OL.pdf); [Achieve Life Sciences SRNT ORCA-OL data announcement (2026)](https://achievelifesciences.com/achieve-presents-orca-ol-data-at-srnt/)

<a id="heading-3.1.4"></a>

#### 3.1.4 ORCA-1

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Dose and schedule selection

> “various dosing schedules”

Source: [Achieve Life Sciences ORCA-1](https://achievelifesciences.com/products/phase-2-orca-1-trial/)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Trial period

| Characteristic | Quoted value |
| --- | --- |
| First visit date | “20 November 2018” |
| Completion date | “23 April 2019” |

Source: [Nides et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8403245/)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Phase 2b trial design

> “ORCA-1 was a double-blind, randomized, placebo-controlled clinical trial that provided cytisinicline or placebo tablets plus behavioral support for 25 days.”

Source: [Nides et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8403245/)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Cigarette-use eligibility

| Characteristic | Quoted value |
| --- | --- |
| Baseline daily cigarette threshold | “>10” |

Source: [Nides et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8403245/)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Cytisinicline dose levels

| Characteristic | Quoted value |
| --- | --- |
| Lower tablet dose | “1.5 mg” |
| Higher tablet dose | “3 mg” |

Source: [Nides et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8403245/)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Percentage of Expected Cigarettes Smoked as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Primary smoking-reduction endpoint

> “percentage of expected cigarettes smoked”

Source: [Nides et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8403245/)

<a id="topic-3.1.4.6.1-2"></a>

###### Secondary week-4 abstinence definition

> “CO-verified 7-day point-prevalence abstinence rates at end of treatment”

Source: [Achieve Life Sciences ORCA-1](https://achievelifesciences.com/products/phase-2-orca-1-trial/)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Randomized participants

| Characteristic | Quoted value |
| --- | --- |
| Total randomized | “254” |

Source: [Nides et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8403245/)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Analysis principle

> “intent-to-treat”

Source: [Nides et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8403245/)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Medication adherence

> “Adherence to study treatment was 98% in the 3mg TID arm”

Source: [Achieve Life Sciences ORCA-1](https://achievelifesciences.com/products/phase-2-orca-1-trial/)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Baseline age and smoking

| Characteristic | Quoted value |
| --- | --- |
| Mean age, years | “48.4” |
| Mean cigarettes per day | “18.2” |

Source: [Nides et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8403245/)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Cytisinicline 3 mg three times daily versus placebo

| Outcome                          | Cytisinicline | Placebo |     P value |
| -------------------------------- | ------------: | ------: | ----------: |
| Four-week abstinence             |         “50%” |   “10%” | “p < 0.001” |
| Continuous abstinence, weeks 5–8 |         “30%” |    “8%” | “p = 0.005” |

Source: [Achieve Life Sciences ORCA-1](https://achievelifesciences.com/products/phase-2-orca-1-trial/)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Serious and severe adverse events

> “No serious or severe adverse events reported”

Source: [Achieve Life Sciences ORCA-1](https://achievelifesciences.com/products/phase-2-orca-1-trial/)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

The primary endpoint measured cigarette reduction, not sustained smoking cessation. The table’s four-week abstinence label refers to seven-day point-prevalence abstinence at the end of treatment, not four weeks of continuous abstinence. Continuous abstinence was evaluated separately during weeks 5–8.

Source: [Nides et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8403245/); [Achieve Life Sciences ORCA-1](https://achievelifesciences.com/products/phase-2-orca-1-trial/)

<a id="heading-3.1.5"></a>

#### 3.1.5 ORCA-V1

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Vaping-cessation objective

> “abstinence from e-cigarette use”

Source: [Rigotti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11074928/)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Trial period

| Characteristic | Quoted value |
| --- | --- |
| First month | “July 2022” |
| Last month | “February 2023” |

Source: [Rigotti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11074928/)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Blinding and allocation

| Characteristic | Quoted value |
| --- | --- |
| Blinding | “double-blind” |
| Allocation | “randomized” |

Source: [Rigotti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11074928/)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Current cigarette-smoking exclusion

> “did not currently smoke cigarettes”

Source: [Rigotti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11074928/)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Dose schedule

| Characteristic | Quoted value |
| --- | --- |
| Cytisinicline dose, mg | “3” |
| Daily dosing frequency | “3” |
| Treatment duration, weeks | “12” |

Source: [Rigotti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11074928/)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Continuous E-cigarette Abstinence as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Primary endpoint assessment

| Characteristic | Quoted value |
| --- | --- |
| Continuous vaping-abstinence interval, weeks | “9-12” |

Source: [Rigotti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11074928/)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Randomized participants

| Characteristic | Quoted value |
| --- | --- |
| Cytisinicline | “107” |
| Placebo | “53” |

Source: [Rigotti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11074928/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Classification of missing outcomes

> “nonabstinence”

Source: [Rigotti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11074928/)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Trial completion

| Characteristic | Quoted value |
| --- | --- |
| Participants completing follow-up | “131” |

Source: [Rigotti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11074928/)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Baseline age

| Characteristic | Quoted value |
| --- | --- |
| Mean age, years | “33.6” |

Source: [Rigotti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11074928/)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Vaping cessation during weeks 9 to 12

| Cytisinicline | Placebo | Effect estimate                       | P value   |
| ------------- | ------- | ------------------------------------- | --------- |
| “31.8%”       | “15.1%” | “odds ratio, 2.64; 95% CI, 1.06-7.10” | “P = .04” |

Source: [Rigotti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11074928/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Adverse-event discontinuations

| Characteristic | Quoted value |
| --- | --- |
| Participants discontinuing cytisinicline because of an adverse event | “4” |

Source: [Rigotti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11074928/)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

This study enrolled adults who vaped but did not currently smoke cigarettes. It therefore provides supporting evidence for vaping cessation rather than a direct estimate of smoking-cessation efficacy. The investigators called for a larger trial with longer follow-up.

Source: [Rigotti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11074928/)

<a id="topic-3.1.5.9-2"></a>

###### Need for confirmation

> “These results need confirmation in a larger trial with longer follow-up.”

Source: [Rigotti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11074928/)

<a id="heading-3.1.6"></a>

#### 3.1.6 ISRCTN37568749

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Cessation efficacy objective

> “efficacy and safety”

Source: [West et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21991893/)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

No evidence found.

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Blinded randomized design

> “single-center, randomized, double-blind, placebo-controlled trial”

Source: [West et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21991893/)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Study population

> “smokers”

Source: [West et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21991893/)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Treatment and follow-up

| Characteristic | Quoted value |
| --- | --- |
| Treatment duration | “25 days” |
| Behavioral intervention | “minimal amount of counseling” |

Source: [West et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21991893/)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Continuous Smoking Abstinence as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

###### Primary endpoint

> “sustained, biochemically verified smoking abstinence”

Source: [West et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21991893/)

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Enrollment

| Characteristic | Quoted value |
| --- | --- |
| Randomized participants | “740” |
| Participants per treatment group | “370” |

Source: [West et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21991893/)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Sustained 12-month abstinence

| Cytisine                 | Placebo                 |
| ------------------------ | ----------------------- |
| “8.4% (31 participants)” | “2.4% (9 participants)” |

Source: [West et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21991893/)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Gastrointestinal adverse events

| Characteristic | Quoted value |
| --- | --- |
| Absolute excess with cytisine, percentage points | “5.7” |

Source: [West et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21991893/)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

This was a single-center trial with minimal counseling and a 25-day cytisine regimen. Its results do not directly test the 6-week or 12-week, 3 mg three-times-daily regimen evaluated in ORCA-2.

Source: [West et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21991893/); [Rigotti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10336611/)

<a id="heading-3.1.7"></a>

#### 3.1.7 ACTRN12610000590066

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

###### Noninferiority objective

> “at least as effective as nicotine-replacement therapy”

Source: [Walker et al. (2014)](https://www.asat.org.ar/images/comunidad/publicaciones/cistisina.pdf)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

###### Country

> “New Zealand”

Source: [Walker et al. (2014)](https://www.asat.org.ar/images/comunidad/publicaciones/cistisina.pdf)

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Pragmatic trial design

> “pragmatic, open-label, noninferiority trial”

Source: [Walker et al. (2014)](https://www.asat.org.ar/images/comunidad/publicaciones/cistisina.pdf)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

###### Quitline population

> “adult daily smokers”

Source: [Walker et al. (2014)](https://www.asat.org.ar/images/comunidad/publicaciones/cistisina.pdf)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

###### Treatment duration

| Characteristic | Quoted value |
| --- | --- |
| Cytisine course, days | “25” |
| Nicotine replacement therapy | “8 weeks” |

Source: [Walker et al. (2014)](https://www.asat.org.ar/images/comunidad/publicaciones/cistisina.pdf)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using Continuous Smoking Abstinence as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

###### Primary outcome

| Characteristic | Quoted value |
| --- | --- |
| Ascertainment | “self-reported” |
| Continuous-abstinence assessment | “1 month” |

Source: [Walker et al. (2014)](https://www.asat.org.ar/images/comunidad/publicaciones/cistisina.pdf)

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Randomized participants

| Characteristic | Quoted value |
| --- | --- |
| Total randomized | “1310” |

Source: [Walker et al. (2014)](https://www.asat.org.ar/images/comunidad/publicaciones/cistisina.pdf)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### Continuous abstinence at 1 month

> “40% of participants receiving cytisine (264 of 655) and 31% of participants receiving nicotine-replacement therapy (203 of 655)”

Source: [Walker et al. (2014)](https://www.asat.org.ar/images/comunidad/publicaciones/cistisina.pdf)

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

###### Participants reporting adverse events

| Characteristic | Quoted value |
| --- | --- |
| Cytisine | “204” |
| Nicotine replacement therapy | “134” |

Source: [Walker et al. (2014)](https://www.asat.org.ar/images/comunidad/publicaciones/cistisina.pdf)

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary

Treatment was open-label and the primary outcome was self-reported abstinence at one month. Cytisine and nicotine replacement therapy were given for different durations. These features limit blinding and comparability with trials using biochemical verification as the primary outcome.

Source: [Walker et al. (2014)](https://www.asat.org.ar/images/comunidad/publicaciones/cistisina.pdf)

<a id="heading-3.1.8"></a>

#### 3.1.8 NCT02957786

<a id="heading-3.1.8.1"></a>

##### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

###### Comparative objective

> “non-inferiority”

Source: [Walker et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/add.15489)

<a id="heading-3.1.8.2"></a>

##### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

###### Country

> “New Zealand”

Source: [Walker et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/add.15489)

<a id="heading-3.1.8.3"></a>

##### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

###### Allocation and masking

> “open-label”

Source: [Walker et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/add.15489)

<a id="heading-3.1.8.4"></a>

##### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

###### Population

> “Māori”

Source: [Walker et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/add.15489)

<a id="heading-3.1.8.5"></a>

##### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

###### Treatment duration

| Characteristic | Quoted value |
| --- | --- |
| Cytisine and varenicline courses | “12 weeks” |

Source: [Walker et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/add.15489)

<a id="heading-3.1.8.6"></a>

##### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

###### 3.1.8.6.1 Rationale for Using Continuous Smoking Abstinence as the Primary Endpoint

<a id="topic-3.1.8.6.1-1"></a>

###### Primary outcome timing

| Characteristic | Quoted value |
| --- | --- |
| Verified continuous-abstinence assessment | “6 months” |

Source: [Walker et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/add.15489)

<a id="heading-3.1.8.7"></a>

##### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

###### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

###### Planned and actual enrollment

| Characteristic | Quoted value |
| --- | --- |
| Planned participants | “2140” |
| Randomized participants | “679” |

Source: [Walker et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/add.15489)

<a id="heading-3.1.8.7.2"></a>

###### 3.1.8.7.2 Description of Analysis Sets

<a id="topic-3.1.8.7.2-1"></a>

###### Missing-data analysis

> “multiple imputation”

Source: [Walker et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/add.15489)

<a id="heading-3.1.8.8"></a>

##### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

###### 3.1.8.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.8.8.2"></a>

###### 3.1.8.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.8.8.3"></a>

###### 3.1.8.8.3 Efficacy Results

<a id="topic-3.1.8.8.3-1"></a>

###### Verified continuous abstinence

> “Verified continuous abstinence rates at 6 months post-quit date were 12.1% (41 of 337) for cytisine versus 7.9% (27 of 342) for varenicline”

Source: [Walker et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/add.15489)

<a id="heading-3.1.8.8.4"></a>

###### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.8.8.5"></a>

###### 3.1.8.8.5 Safety Results

<a id="topic-3.1.8.8.5-1"></a>

###### Reported adverse events

| Characteristic | Quoted value |
| --- | --- |
| Cytisine events | “313” |
| Varenicline events | “509” |

Source: [Walker et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/add.15489)

<a id="heading-3.1.8.9"></a>

##### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

###### Summary

Enrollment was 679 participants compared with a planned 2,140. The open-label design and recruitment below target limit precision and leave potential reporting and performance bias. The population and 12-week cytisine regimen differ from other historical cytisine trials.

Source: [Walker et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/add.15489)

<a id="heading-3.1.9"></a>

#### 3.1.9 ACTRN12616001654448

<a id="heading-3.1.9.1"></a>

##### 3.1.9.1 Objective

<a id="topic-3.1.9.1-1"></a>

###### Primary comparison

> “noninferiority”

Source: [Courtney et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261608/)

<a id="heading-3.1.9.2"></a>

##### 3.1.9.2 Location and Study Date

<a id="topic-3.1.9.2-1"></a>

###### Country

> “Australia”

Source: [Courtney et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261608/)

<a id="heading-3.1.9.3"></a>

##### 3.1.9.3 Study Design

<a id="topic-3.1.9.3-1"></a>

###### Trial masking

> “open-label”

Source: [Courtney et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261608/)

<a id="heading-3.1.9.4"></a>

##### 3.1.9.4 Eligibility Criteria

<a id="topic-3.1.9.4-1"></a>

###### Population

> “adult daily smokers”

Source: [Courtney et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261608/)

<a id="heading-3.1.9.5"></a>

##### 3.1.9.5 Treatment

<a id="topic-3.1.9.5-1"></a>

###### Treatment duration

| Characteristic | Quoted value |
| --- | --- |
| Cytisine, days | “25” |
| Varenicline, days | “84” |

Source: [Courtney et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261608/)

<a id="heading-3.1.9.6"></a>

##### 3.1.9.6 Study Outcomes

<a id="heading-3.1.9.6.1"></a>

###### 3.1.9.6.1 Rationale for Using Continuous Smoking Abstinence as the Primary Endpoint

<a id="topic-3.1.9.6.1-1"></a>

###### Primary outcome

| Characteristic | Quoted value |
| --- | --- |
| Continuous-abstinence assessment | “6 months” |

Source: [Courtney et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261608/)

<a id="heading-3.1.9.7"></a>

##### 3.1.9.7 Statistical Analysis Description

<a id="heading-3.1.9.7.1"></a>

###### 3.1.9.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.9.7.1-1"></a>

###### Randomized sample

| Characteristic | Quoted value |
| --- | --- |
| Total participants | “1452” |
| Cytisine | “725” |
| Varenicline | “727” |

Source: [Courtney et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261608/)

<a id="heading-3.1.9.7.2"></a>

###### 3.1.9.7.2 Description of Analysis Sets

<a id="topic-3.1.9.7.2-1"></a>

###### Noninferiority threshold

| Characteristic | Quoted value |
| --- | --- |
| Margin | “5%” |
| One-sided significance level | “.025” |

Source: [Courtney et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261608/)

<a id="heading-3.1.9.8"></a>

##### 3.1.9.8 Results

<a id="heading-3.1.9.8.1"></a>

###### 3.1.9.8.1 Participant Disposition

<a id="topic-3.1.9.8.1-1"></a>

###### Follow-up completion

| Characteristic | Quoted value |
| --- | --- |
| Participants completing follow-up | “1108” |

Source: [Courtney et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261608/)

<a id="heading-3.1.9.8.2"></a>

###### 3.1.9.8.2 Baseline Characteristics

<a id="topic-3.1.9.8.2-1"></a>

###### Baseline age and sex

| Characteristic | Quoted value |
| --- | --- |
| Mean age, years | “42.9” |
| Female participants | “51.1%” |

Source: [Courtney et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261608/)

<a id="heading-3.1.9.8.3"></a>

###### 3.1.9.8.3 Efficacy Results

<a id="topic-3.1.9.8.3-1"></a>

###### Verified 6-month continuous abstinence

| Cytisine | Varenicline |
| -------- | ----------- |
| “11.7%”  | “13.3%”     |

Source: [Courtney et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261608/)

<a id="topic-3.1.9.8.3-2"></a>

###### Primary noninferiority analysis

> “This primary analysis did not confirm noninferiority of cytisine compared with varenicline at the 2.5% level of significance”

Source: [Courtney et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261608/)

<a id="topic-3.1.9.8.3-3"></a>

###### Risk difference and investigator conclusion

> “Verified 6-month continuous abstinence rates were 11.7% for the cytisine group and 13.3% for the varenicline group (risk difference, −1.62% [1-sided 97.5% CI, −5.02% to ∞]; P = .03 for noninferiority).”
> “Among daily smokers willing to quit, cytisine treatment for 25 days, compared with varenicline treatment for 84 days, failed to demonstrate noninferiority regarding smoking cessation.”

Source: [Courtney et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261608/)

<a id="heading-3.1.9.8.4"></a>

###### 3.1.9.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.9.8.5"></a>

###### 3.1.9.8.5 Safety Results

<a id="topic-3.1.9.8.5-1"></a>

###### Reported adverse-event counts

| Characteristic | Quoted value |
| --- | --- |
| Cytisine | “997” |
| Varenicline | “1206” |

Source: [Courtney et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261608/)

<a id="topic-3.1.9.8.5-2"></a>

###### Self-reported adverse events: incident rate ratio against varenicline

> “Self-reported adverse events occurred less frequently in the cytisine group (997 events among 482 participants) compared with the varenicline group (1206 events among 510 participants) and the incident rate ratio was 0.88 (95% CI, 0.81 to 0.95; P = .002).”

Source: [Courtney et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261608/)

<a id="heading-3.1.9.9"></a>

##### 3.1.9.9 Study Limitations

<a id="topic-3.1.9.9-1"></a>

###### Summary

The primary analysis did not establish noninferiority. Cytisine was administered for 25 days and varenicline for 84 days, so the comparison combines differences in medication and duration. The trial was open-label.

Source: [Courtney et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8261608/)

<a id="heading-3.1.10"></a>

#### 3.1.10 ISRCTN43811467

<a id="heading-3.1.10.1"></a>

##### 3.1.10.1 Objective

<a id="topic-3.1.10.1-1"></a>

###### Treatment objective

> “tobacco dependence”

Source: [Dogar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33069301/)

<a id="heading-3.1.10.2"></a>

##### 3.1.10.2 Location and Study Date

<a id="topic-3.1.10.2-1"></a>

###### Countries

> “Bangladesh and Pakistan”

Source: [Dogar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33069301/)

<a id="heading-3.1.10.3"></a>

##### 3.1.10.3 Study Design

<a id="topic-3.1.10.3-1"></a>

###### Trial masking and control

> “randomised, double-blind, placebo-controlled”

Source: [Dogar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33069301/)

<a id="heading-3.1.10.4"></a>

##### 3.1.10.4 Eligibility Criteria

<a id="topic-3.1.10.4-1"></a>

###### Tuberculosis population

> “pulmonary tuberculosis”

Source: [Dogar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33069301/)

<a id="heading-3.1.10.5"></a>

##### 3.1.10.5 Treatment

<a id="topic-3.1.10.5-1"></a>

###### Regimen

| Characteristic | Quoted value |
| --- | --- |
| Treatment course | “25 days” |
| Concomitant intervention | “brief behavioural support” |

Source: [Dogar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33069301/)

<a id="heading-3.1.10.6"></a>

##### 3.1.10.6 Study Outcomes

<a id="heading-3.1.10.6.1"></a>

###### 3.1.10.6.1 Rationale for Using Continuous Smoking Abstinence as the Primary Endpoint

<a id="topic-3.1.10.6.1-1"></a>

###### Primary assessment

| Characteristic | Quoted value |
| --- | --- |
| Continuous-abstinence follow-up, months | “6” |

Source: [Dogar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33069301/)

<a id="heading-3.1.10.7"></a>

##### 3.1.10.7 Statistical Analysis Description

<a id="heading-3.1.10.7.1"></a>

###### 3.1.10.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.10.7.1-1"></a>

###### Randomized participants

| Characteristic | Quoted value |
| --- | --- |
| Total | “2472” |
| Cytisine | “1239” |
| Placebo | “1233” |

Source: [Dogar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33069301/)

<a id="heading-3.1.10.7.2"></a>

###### 3.1.10.7.2 Description of Analysis Sets

<a id="topic-3.1.10.7.2-1"></a>

###### Primary analysis population

> “intention-to-treat”

Source: [Dogar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33069301/)

<a id="heading-3.1.10.8"></a>

##### 3.1.10.8 Results

<a id="heading-3.1.10.8.1"></a>

###### 3.1.10.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.10.8.2"></a>

###### 3.1.10.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.10.8.3"></a>

###### 3.1.10.8.3 Efficacy Results

<a id="topic-3.1.10.8.3-1"></a>

###### Investigators’ interpretation

> “Our findings do not support the addition of cytisine to brief behavioural support for the treatment of tobacco dependence in patients with tuberculosis.”

Source: [Dogar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33069301/)

<a id="topic-3.1.10.8.3-2"></a>

###### Continuous abstinence at 6 months

| Characteristic | Quoted value |
| --- | --- |
| Cytisine participants abstinent | “401” |
| Placebo participants abstinent | “366” |

Source: [Dogar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33069301/)

<a id="heading-3.1.10.8.4"></a>

###### 3.1.10.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.10.8.5"></a>

###### 3.1.10.8.5 Safety Results

<a id="topic-3.1.10.8.5-1"></a>

###### Participants with serious adverse events

| Characteristic | Quoted value |
| --- | --- |
| Cytisine | “53” |
| Placebo | “46” |

Source: [Dogar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33069301/)

<a id="heading-3.1.10.9"></a>

##### 3.1.10.9 Study Limitations

<a id="topic-3.1.10.9-1"></a>

###### Summary

The study population had pulmonary tuberculosis, and both groups received brief behavioral support. The investigators did not support adding cytisine in this setting. Results should not be treated as a direct evaluation of the ORCA regimen in the general smoking population.

Source: [Dogar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33069301/); [Rigotti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10336611/)

<a id="heading-3.1.11"></a>

#### 3.1.11 SMILE

<a id="heading-3.1.11.1"></a>

##### 3.1.11.1 Objective

<a id="topic-3.1.11.1-1"></a>

###### Smoking-cessation objective

> “smoking cessation”

Source: [Pastorino et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35908731/)

<a id="heading-3.1.11.2"></a>

##### 3.1.11.2 Location and Study Date

<a id="topic-3.1.11.2-1"></a>

###### Country

> “Italy”

Source: [Pastorino et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35908731/)

<a id="heading-3.1.11.3"></a>

##### 3.1.11.3 Study Design

<a id="topic-3.1.11.3-1"></a>

###### Trial setting and design

> “single-center, randomized, controlled trial”

Source: [Pastorino et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35908731/)

<a id="heading-3.1.11.4"></a>

##### 3.1.11.4 Eligibility Criteria

<a id="topic-3.1.11.4-1"></a>

###### Screening population

> “current heavy tobacco users”

Source: [Pastorino et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35908731/)

<a id="heading-3.1.11.5"></a>

##### 3.1.11.5 Treatment

<a id="topic-3.1.11.5-1"></a>

###### Concomitant intervention

> “counseling”

Source: [Pastorino et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35908731/)

<a id="heading-3.1.11.6"></a>

##### 3.1.11.6 Study Outcomes

<a id="heading-3.1.11.6.1"></a>

###### 3.1.11.6.1 Rationale for Using Continuous Smoking Abstinence as the Primary Endpoint

<a id="topic-3.1.11.6.1-1"></a>

###### Primary outcome

| Characteristic | Quoted value |
| --- | --- |
| Continuous-abstinence assessment | “12 months” |

Source: [Pastorino et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35908731/)

<a id="heading-3.1.11.7"></a>

##### 3.1.11.7 Statistical Analysis Description

<a id="heading-3.1.11.7.1"></a>

###### 3.1.11.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.11.7.1-1"></a>

###### Randomized population

| Characteristic | Quoted value |
| --- | --- |
| Total | “869” |
| Cytisine plus counseling | “470” |
| Counseling alone | “399” |

Source: [Pastorino et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35908731/)

<a id="heading-3.1.11.7.2"></a>

###### 3.1.11.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.11.8"></a>

##### 3.1.11.8 Results

<a id="heading-3.1.11.8.1"></a>

###### 3.1.11.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.11.8.2"></a>

###### 3.1.11.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.11.8.3"></a>

###### 3.1.11.8.3 Efficacy Results

<a id="topic-3.1.11.8.3-1"></a>

###### Biochemically verified continuous abstinence

| Characteristic | Quoted value |
| --- | --- |
| Cytisine plus counseling | “32.1%” |
| Counseling alone | “7.3%” |
| Adjusted odds ratio | “7.2” |

Source: [Pastorino et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35908731/)

<a id="heading-3.1.11.8.4"></a>

###### 3.1.11.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.11.8.5"></a>

###### 3.1.11.8.5 Safety Results

<a id="topic-3.1.11.8.5-1"></a>

###### Participants reporting adverse events

| Characteristic | Quoted value |
| --- | --- |
| Cytisine group | “196” |
| Control group | “133” |

Source: [Pastorino et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35908731/)

<a id="heading-3.1.11.9"></a>

##### 3.1.11.9 Study Limitations

<a id="topic-3.1.11.9-1"></a>

###### Summary

This single-center trial enrolled current heavy smokers in lung-cancer screening. Its control was counseling alone rather than placebo tablets or an active cessation medication. Applicability to other smoking populations and comparative tolerability against active medication remain uncertain.

Source: [Pastorino et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35908731/)

<a id="heading-3.1.12"></a>

#### 3.1.12 TCTR20180312001

<a id="heading-3.1.12.1"></a>

##### 3.1.12.1 Objective

<a id="topic-3.1.12.1-1"></a>

###### Community-pharmacy objective

> “smoking cessation”

Source: [Phusahat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9603285/)

<a id="heading-3.1.12.2"></a>

##### 3.1.12.2 Location and Study Date

<a id="topic-3.1.12.2-1"></a>

###### Country

> “Thailand”

Source: [Phusahat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9603285/)

<a id="heading-3.1.12.3"></a>

##### 3.1.12.3 Study Design

<a id="topic-3.1.12.3-1"></a>

###### Trial design

> “double-blinded randomized placebo-controlled”

Source: [Phusahat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9603285/)

<a id="heading-3.1.12.4"></a>

##### 3.1.12.4 Eligibility Criteria

<a id="topic-3.1.12.4-1"></a>

###### Eligibility thresholds

| Characteristic | Quoted value |
| --- | --- |
| Age, years | “>18” |
| Daily tobacco consumption | “>10 tobaccos/day” |

Source: [Phusahat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9603285/)

<a id="heading-3.1.12.5"></a>

##### 3.1.12.5 Treatment

<a id="topic-3.1.12.5-1"></a>

###### Behavioral intervention

> “five sessions of counselling”

Source: [Phusahat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9603285/)

<a id="heading-3.1.12.6"></a>

##### 3.1.12.6 Study Outcomes

<a id="heading-3.1.12.6.1"></a>

###### 3.1.12.6.1 Rationale for Using Continuous Smoking Abstinence as the Primary Endpoint

<a id="topic-3.1.12.6.1-1"></a>

###### Primary endpoint

| Characteristic | Quoted value |
| --- | --- |
| Continuous-abstinence assessment | “week 48” |

Source: [Phusahat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9603285/)

<a id="heading-3.1.12.7"></a>

##### 3.1.12.7 Statistical Analysis Description

<a id="heading-3.1.12.7.1"></a>

###### 3.1.12.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.12.7.1-1"></a>

###### Treatment groups

| Characteristic | Quoted value |
| --- | --- |
| Cytisine participants | “67” |
| Placebo participants | “65” |

Source: [Phusahat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9603285/)

<a id="heading-3.1.12.7.2"></a>

###### 3.1.12.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.12.8"></a>

##### 3.1.12.8 Results

<a id="heading-3.1.12.8.1"></a>

###### 3.1.12.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.12.8.2"></a>

###### 3.1.12.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.12.8.3"></a>

###### 3.1.12.8.3 Efficacy Results

<a id="topic-3.1.12.8.3-1"></a>

###### Continuous abstinence at week 48

> “The CARs were determined to be 14.93% and 6.15% for cytisine and placebo, respectively, at week 48.”

Source: [Phusahat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9603285/)

<a id="topic-3.1.12.8.3-2"></a>

###### Week-48 treatment comparison

| Characteristic | Quoted value |
| --- | --- |
| Relative risk | “2.41” |
| 95% confidence interval | “0.80-7.35” |
| P value | “0.102” |

Source: [Phusahat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9603285/)

<a id="heading-3.1.12.8.4"></a>

###### 3.1.12.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.12.8.5"></a>

###### 3.1.12.8.5 Safety Results

<a id="topic-3.1.12.8.5-1"></a>

###### Reported adverse-event categories

> “gastrointestinal and neurological adverse events”

Source: [Phusahat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9603285/)

<a id="heading-3.1.12.9"></a>

##### 3.1.12.9 Study Limitations

<a id="topic-3.1.12.9-1"></a>

###### Summary

The trial included 67 participants receiving cytisine and 65 receiving placebo. The week-48 relative-risk confidence interval included no difference (relative risk 2.41; 95% confidence interval 0.80–7.35; P = 0.102). The small groups limit precision and assessment of uncommon harms.

Source: [Phusahat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9603285/)

<a id="heading-3.1.13"></a>

#### 3.1.13 Cytisine versus nortriptyline

<a id="heading-3.1.13.1"></a>

##### 3.1.13.1 Objective

<a id="topic-3.1.13.1-1"></a>

###### Comparative objective

> “smoking cessation”

Source: [Rungruanghiranya et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1111/resp.14787)

<a id="heading-3.1.13.2"></a>

##### 3.1.13.2 Location and Study Date

No evidence found.

<a id="heading-3.1.13.3"></a>

##### 3.1.13.3 Study Design

<a id="topic-3.1.13.3-1"></a>

###### Trial design

> “multicentre, randomized, double-blinded, placebo-controlled trial”

Source: [Rungruanghiranya et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1111/resp.14787)

<a id="heading-3.1.13.4"></a>

##### 3.1.13.4 Eligibility Criteria

<a id="topic-3.1.13.4-1"></a>

###### Eligibility thresholds

| Characteristic | Quoted value |
| --- | --- |
| Minimum age, years | “20” |
| Minimum cigarettes per day | “10” |

Source: [Rungruanghiranya et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1111/resp.14787)

<a id="heading-3.1.13.5"></a>

##### 3.1.13.5 Treatment

<a id="topic-3.1.13.5-1"></a>

###### Treatment courses

| Characteristic | Quoted value |
| --- | --- |
| Cytisine | “25-day” |
| Nortriptyline | “12-week” |

Source: [Rungruanghiranya et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1111/resp.14787)

<a id="heading-3.1.13.6"></a>

##### 3.1.13.6 Study Outcomes

<a id="heading-3.1.13.6.1"></a>

###### 3.1.13.6.1 Rationale for Using Continuous Smoking Abstinence as the Primary Endpoint

<a id="topic-3.1.13.6.1-1"></a>

###### Primary outcome

> “biochemically verified continuous abstinence rate”

Source: [Rungruanghiranya et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1111/resp.14787)

<a id="heading-3.1.13.7"></a>

##### 3.1.13.7 Statistical Analysis Description

<a id="heading-3.1.13.7.1"></a>

###### 3.1.13.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.13.7.1-1"></a>

###### Randomized participants

| Characteristic | Quoted value |
| --- | --- |
| Total | “1086” |
| Cytisine | “540” |
| Nortriptyline | “546” |

Source: [Rungruanghiranya et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1111/resp.14787)

<a id="heading-3.1.13.7.2"></a>

###### 3.1.13.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.13.8"></a>

##### 3.1.13.8 Results

<a id="heading-3.1.13.8.1"></a>

###### 3.1.13.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.13.8.2"></a>

###### 3.1.13.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.13.8.3"></a>

###### 3.1.13.8.3 Efficacy Results

<a id="topic-3.1.13.8.3-1"></a>

###### Continuous abstinence at 12 months

> “The 12-month CAR was 12.22% for cytisine and 9.52% for nortriptyline”
> “the relative risk was 1.28 (95% CI; 0.91–1.81).”

Source: [Rungruanghiranya et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1111/resp.14787)

<a id="heading-3.1.13.8.4"></a>

###### 3.1.13.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.13.8.5"></a>

###### 3.1.13.8.5 Safety Results

<a id="topic-3.1.13.8.5-1"></a>

###### Adverse-event characterization

> “minimal and well-tolerated.”

Source: [Rungruanghiranya et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1111/resp.14787)

<a id="heading-3.1.13.9"></a>

##### 3.1.13.9 Study Limitations

<a id="topic-3.1.13.9-1"></a>

###### Summary

The observed relative-risk confidence interval, 0.91–1.81, includes no difference. The nonsignificant comparison does not by itself establish equivalence. Cytisine and nortriptyline were administered for different durations.

Source: [Rungruanghiranya et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1111/resp.14787)

<a id="heading-3.1.14"></a>

#### 3.1.14 Cytisine versus varenicline in primary care

<a id="heading-3.1.14.1"></a>

##### 3.1.14.1 Objective

No evidence found.

<a id="heading-3.1.14.2"></a>

##### 3.1.14.2 Location and Study Date

No evidence found.

<a id="heading-3.1.14.3"></a>

##### 3.1.14.3 Study Design

No evidence found.

<a id="heading-3.1.14.4"></a>

##### 3.1.14.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.14.5"></a>

##### 3.1.14.5 Treatment

No evidence found.

<a id="heading-3.1.14.6"></a>

##### 3.1.14.6 Study Outcomes

<a id="heading-3.1.14.6.1"></a>

###### 3.1.14.6.1 Rationale for Using Continuous Smoking Abstinence as the Primary Endpoint

No evidence found.

<a id="heading-3.1.14.7"></a>

##### 3.1.14.7 Statistical Analysis Description

<a id="heading-3.1.14.7.1"></a>

###### 3.1.14.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.14.7.2"></a>

###### 3.1.14.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.14.8"></a>

##### 3.1.14.8 Results

<a id="heading-3.1.14.8.1"></a>

###### 3.1.14.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.14.8.2"></a>

###### 3.1.14.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.14.8.3"></a>

###### 3.1.14.8.3 Efficacy Results

Additional sources: [Oreskovic et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37291049/)

<a id="heading-3.1.14.8.4"></a>

###### 3.1.14.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.14.8.5"></a>

###### 3.1.14.8.5 Safety Results

No evidence found.

<a id="heading-3.1.14.9"></a>

##### 3.1.14.9 Study Limitations

No evidence found.

<a id="heading-3.1.15"></a>

#### 3.1.15 NCT04286295

<a id="heading-3.1.15.1"></a>

##### 3.1.15.1 Objective

<a id="topic-3.1.15.1-1"></a>

###### Pilot objective

> “feasibility of a definitive trial”

Source: [Mir et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12399143/)

<a id="heading-3.1.15.2"></a>

##### 3.1.15.2 Location and Study Date

No evidence found.

<a id="heading-3.1.15.3"></a>

##### 3.1.15.3 Study Design

<a id="topic-3.1.15.3-1"></a>

###### Design

> “2-group, single-site pilot randomized controlled trial”

Source: [Mir et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12399143/)

<a id="heading-3.1.15.4"></a>

##### 3.1.15.4 Eligibility Criteria

<a id="topic-3.1.15.4-1"></a>

###### Clinical population

> “Adults with heart disease”

Source: [Mir et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12399143/)

<a id="heading-3.1.15.5"></a>

##### 3.1.15.5 Treatment

<a id="topic-3.1.15.5-1"></a>

###### Treatment course

| Characteristic | Quoted value |
| --- | --- |
| Cytisine or combination nicotine replacement therapy | “25 days” |

Source: [Mir et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12399143/)

<a id="heading-3.1.15.6"></a>

##### 3.1.15.6 Study Outcomes

<a id="heading-3.1.15.6.1"></a>

###### 3.1.15.6.1 Rationale for Using Recruitment and Treatment Adherence as the Primary Feasibility Endpoints

<a id="topic-3.1.15.6.1-1"></a>

###### Primary feasibility measures

> “participant recruitment and treatment adherence”

Source: [Mir et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12399143/)

<a id="heading-3.1.15.7"></a>

##### 3.1.15.7 Statistical Analysis Description

<a id="heading-3.1.15.7.1"></a>

###### 3.1.15.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.15.7.1-1"></a>

###### Recruitment

| Characteristic | Quoted value |
| --- | --- |
| Recruited participants | “13” |

Source: [Mir et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12399143/)

<a id="heading-3.1.15.7.2"></a>

###### 3.1.15.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.15.8"></a>

##### 3.1.15.8 Results

<a id="heading-3.1.15.8.1"></a>

###### 3.1.15.8.1 Participant Disposition

<a id="topic-3.1.15.8.1-1"></a>

###### Recruitment and completion

> “We recruited 13 participants (41% of eligible), of whom 9 (69%) completed the study.”

Source: [Mir et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12399143/)

<a id="heading-3.1.15.8.2"></a>

###### 3.1.15.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.15.8.3"></a>

###### 3.1.15.8.3 Efficacy Results

<a id="topic-3.1.15.8.3-1"></a>

###### Participants abstinent at day 25

| Characteristic | Quoted value |
| --- | --- |
| Cytisine | “1” |
| Nicotine replacement therapy | “0” |

Source: [Mir et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12399143/)

<a id="heading-3.1.15.8.4"></a>

###### 3.1.15.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.15.8.5"></a>

###### 3.1.15.8.5 Safety Results

No evidence found.

<a id="heading-3.1.15.9"></a>

##### 3.1.15.9 Study Limitations

<a id="topic-3.1.15.9-1"></a>

###### Summary

This pilot recruited 13 participants and nine completed follow-up. It was designed to evaluate recruitment and adherence, not to provide a definitive comparative efficacy estimate. Its end-of-treatment cessation findings are therefore exploratory.

Source: [Mir et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12399143/)

<a id="heading-3.1.16"></a>

#### 3.1.16 RISP

<a id="heading-3.1.16.1"></a>

##### 3.1.16.1 Objective

No evidence found.

<a id="heading-3.1.16.2"></a>

##### 3.1.16.2 Location and Study Date

No evidence found.

<a id="heading-3.1.16.3"></a>

##### 3.1.16.3 Study Design

No evidence found.

<a id="heading-3.1.16.4"></a>

##### 3.1.16.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.16.5"></a>

##### 3.1.16.5 Treatment

No evidence found.

<a id="heading-3.1.16.6"></a>

##### 3.1.16.6 Study Outcomes

<a id="heading-3.1.16.6.1"></a>

###### 3.1.16.6.1 Rationale for Using Continuous Smoking Abstinence as the Primary Endpoint

No evidence found.

<a id="heading-3.1.16.7"></a>

##### 3.1.16.7 Statistical Analysis Description

<a id="heading-3.1.16.7.1"></a>

###### 3.1.16.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.16.7.2"></a>

###### 3.1.16.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.16.8"></a>

##### 3.1.16.8 Results

<a id="heading-3.1.16.8.1"></a>

###### 3.1.16.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.16.8.2"></a>

###### 3.1.16.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.16.8.3"></a>

###### 3.1.16.8.3 Efficacy Results

Additional sources: [Cani et al. (2026)](https://doi.org/10.1016/j.jtho.2026.104071)

<a id="heading-3.1.16.8.4"></a>

###### 3.1.16.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.16.8.5"></a>

###### 3.1.16.8.5 Safety Results

No evidence found.

<a id="heading-3.1.16.9"></a>

##### 3.1.16.9 Study Limitations

No evidence found.

<a id="heading-3.1.17"></a>

#### 3.1.17 CITISILONG

<a id="heading-3.1.17.1"></a>

##### 3.1.17.1 Objective

<a id="topic-3.1.17.1-1"></a>

###### Duration-comparison objective

> “efficacy and safety”

Source: [Rábade Castedo et al. (2026)](https://www.researchprotocols.org/2026/1/e76815)

<a id="heading-3.1.17.2"></a>

##### 3.1.17.2 Location and Study Date

<a id="topic-3.1.17.2-1"></a>

###### Planned centers and country

> “A total of 402 patients from 10 smoking cessation units in Spain will be randomized.”

Source: [Rábade Castedo et al. (2026)](https://www.researchprotocols.org/2026/1/e76815)

<a id="heading-3.1.17.3"></a>

##### 3.1.17.3 Study Design

<a id="topic-3.1.17.3-1"></a>

###### Trial masking

> “open-label”

Source: [Rábade Castedo et al. (2026)](https://www.researchprotocols.org/2026/1/e76815)

<a id="heading-3.1.17.4"></a>

##### 3.1.17.4 Eligibility Criteria

<a id="topic-3.1.17.4-1"></a>

###### Adult eligibility threshold

| Characteristic | Quoted value |
| --- | --- |
| Minimum age, years | “18” |

Source: [Rábade Castedo et al. (2026)](https://www.researchprotocols.org/2026/1/e76815)

<a id="heading-3.1.17.5"></a>

##### 3.1.17.5 Treatment

<a id="topic-3.1.17.5-1"></a>

###### Planned cytisine durations

| Characteristic | Quoted value |
| --- | --- |
| Standard course, days | “25” |
| Extended course, days | “50” |
| Longest course, days | “75” |

Source: [Rábade Castedo et al. (2026)](https://www.researchprotocols.org/2026/1/e76815)

<a id="heading-3.1.17.6"></a>

##### 3.1.17.6 Study Outcomes

<a id="heading-3.1.17.6.1"></a>

###### 3.1.17.6.1 Rationale for Using Continuous Smoking Abstinence as the Primary Endpoint

<a id="topic-3.1.17.6.1-1"></a>

###### Long-term abstinence assessments

> “6 and 12 months”

Source: [Rábade Castedo et al. (2026)](https://www.researchprotocols.org/2026/1/e76815)

<a id="heading-3.1.17.7"></a>

##### 3.1.17.7 Statistical Analysis Description

<a id="heading-3.1.17.7.1"></a>

###### 3.1.17.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.17.7.1-1"></a>

###### Planned statistical design

| Characteristic | Quoted value |
| --- | --- |
| Target participants | “402” |
| Power | “80%” |
| Anticipated losses | “21%” |

Source: [Rábade Castedo et al. (2026)](https://www.researchprotocols.org/2026/1/e76815)

<a id="heading-3.1.17.7.2"></a>

###### 3.1.17.7.2 Description of Analysis Sets

<a id="topic-3.1.17.7.2-1"></a>

###### Planned analysis set

> “clinically evaluable population”

Source: [Rábade Castedo et al. (2026)](https://www.researchprotocols.org/2026/1/e76815)

<a id="heading-3.1.17.8"></a>

##### 3.1.17.8 Results

<a id="heading-3.1.17.8.1"></a>

###### 3.1.17.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.17.8.2"></a>

###### 3.1.17.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.17.8.3"></a>

###### 3.1.17.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.17.8.4"></a>

###### 3.1.17.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.17.8.5"></a>

###### 3.1.17.8.5 Safety Results

No evidence found.

<a id="heading-3.1.17.9"></a>

##### 3.1.17.9 Study Limitations

<a id="topic-3.1.17.9-1"></a>

###### Summary

The report contains a protocol, not observed cessation or safety results. Planned comparisons are open-label and use 25-, 50-, and 75-day courses. The clinically evaluable analysis population may differ from all randomized participants.

Source: [Rábade Castedo et al. (2026)](https://www.researchprotocols.org/2026/1/e76815)

<a id="heading-3.1.18"></a>

#### 3.1.18 Forty-day cytisine regimen

<a id="heading-3.1.18.1"></a>

##### 3.1.18.1 Objective

<a id="topic-3.1.18.1-1"></a>

###### Regimen objective

> “40-day regimen”

Source: [Tinghino et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11129281/)

<a id="heading-3.1.18.2"></a>

##### 3.1.18.2 Location and Study Date

<a id="topic-3.1.18.2-1"></a>

###### Study period and country

| Characteristic | Quoted value |
| --- | --- |
| Observation period | “2015–2021” |
| Country | “Italy” |

Source: [Tinghino et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11129281/)

<a id="heading-3.1.18.3"></a>

##### 3.1.18.3 Study Design

<a id="topic-3.1.18.3-1"></a>

###### Nonrandomized allocation

> “The sample was not randomized.”

Source: [Tinghino et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11129281/)

<a id="heading-3.1.18.4"></a>

##### 3.1.18.4 Eligibility Criteria

<a id="topic-3.1.18.4-1"></a>

###### Clinical setting

> “smoking cessation centers”

Source: [Tinghino et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11129281/)

<a id="heading-3.1.18.5"></a>

##### 3.1.18.5 Treatment

<a id="topic-3.1.18.5-1"></a>

###### Compared treatment durations

| Characteristic | Quoted value |
| --- | --- |
| Cytisine | “40 days” |
| Varenicline | “12 weeks” |
| Nicotine replacement therapy | “eight weeks” |

Source: [Tinghino et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11129281/)

<a id="heading-3.1.18.6"></a>

##### 3.1.18.6 Study Outcomes

<a id="heading-3.1.18.6.1"></a>

###### 3.1.18.6.1 Rationale for Using Biochemically Confirmed Smoking Abstinence as a Study Endpoint

<a id="topic-3.1.18.6.1-1"></a>

###### Abstinence assessment

| Characteristic | Quoted value |
| --- | --- |
| Follow-up interval | “6 months” |

Source: [Tinghino et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11129281/)

<a id="heading-3.1.18.7"></a>

##### 3.1.18.7 Statistical Analysis Description

<a id="heading-3.1.18.7.1"></a>

###### 3.1.18.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.18.7.1-1"></a>

###### Treatment cohorts

| Characteristic | Quoted value |
| --- | --- |
| Cytisine | “543” |
| Varenicline | “281” |
| Nicotine replacement therapy | “47” |

Source: [Tinghino et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11129281/)

<a id="heading-3.1.18.7.2"></a>

###### 3.1.18.7.2 Description of Analysis Sets

<a id="topic-3.1.18.7.2-1"></a>

###### Continuous-variable comparison

> “t-test”

Source: [Tinghino et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11129281/)

<a id="heading-3.1.18.8"></a>

##### 3.1.18.8 Results

<a id="heading-3.1.18.8.1"></a>

###### 3.1.18.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.18.8.2"></a>

###### 3.1.18.8.2 Baseline Characteristics

<a id="topic-3.1.18.8.2-1"></a>

###### Cytisine group at baseline

| Characteristic | Quoted value |
| --- | --- |
| Mean age, years | “52.5” |

Source: [Tinghino et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11129281/)

<a id="heading-3.1.18.8.3"></a>

###### 3.1.18.8.3 Efficacy Results

<a id="topic-3.1.18.8.3-1"></a>

###### Biochemically confirmed smoking abstinence

| Characteristic | Quoted value |
| --- | --- |
| Cytisine | “50.5%” |
| Varenicline | “55.9%” |
| Nicotine replacement therapy | “51.0%” |

Source: [Tinghino et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11129281/)

<a id="heading-3.1.18.8.4"></a>

###### 3.1.18.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.18.8.5"></a>

###### 3.1.18.8.5 Safety Results

<a id="topic-3.1.18.8.5-1"></a>

###### Cytisine adverse events

| Characteristic | Quoted value |
| --- | --- |
| Participants reporting an adverse event | “24” |
| Percentage | “4.4%” |

Source: [Tinghino et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11129281/)

<a id="heading-3.1.18.9"></a>

##### 3.1.18.9 Study Limitations

<a id="topic-3.1.18.9-1"></a>

###### Summary

Allocation was not randomized, and there was no placebo group or direct comparison with the standard 25-day cytisine regimen. The observed differences cannot establish that extending treatment to 40 days caused improved outcomes.

Source: [Tinghino et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11129281/)

<a id="topic-3.1.18.9-2"></a>

###### Comparator limitations

> “There was no placebo group, and there was no direct comparison with the 25-day scheme.”

Source: [Tinghino et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11129281/)

<a id="heading-3.1.19"></a>

#### 3.1.19 CITOSP

<a id="heading-3.1.19.1"></a>

##### 3.1.19.1 Objective

<a id="topic-3.1.19.1-1"></a>

###### Clinical safety objective

> “CYT safety”

Source: [Tedesco et al. (2025a)](https://link.springer.com/article/10.1007/s11739-025-03888-5)

<a id="heading-3.1.19.2"></a>

##### 3.1.19.2 Location and Study Date

<a id="topic-3.1.19.2-1"></a>

###### Hospital setting

> “Verona University Hospital”

Source: [Tedesco et al. (2025a)](https://link.springer.com/article/10.1007/s11739-025-03888-5)

<a id="topic-3.1.19.2-2"></a>

###### Enrollment years

| Characteristic | Quoted value |
| --- | --- |
| First year | “2021” |
| Last year | “2023” |

Source: [Tedesco et al. (2025a)](https://link.springer.com/article/10.1007/s11739-025-03888-5)

<a id="heading-3.1.19.3"></a>

##### 3.1.19.3 Study Design

<a id="topic-3.1.19.3-1"></a>

###### Observational design

> “observational prospective study”

Source: [Tedesco et al. (2025a)](https://link.springer.com/article/10.1007/s11739-025-03888-5)

<a id="heading-3.1.19.4"></a>

##### 3.1.19.4 Eligibility Criteria

<a id="topic-3.1.19.4-1"></a>

###### Cardiology population

> “hospitalised smokers”

Source: [Tedesco et al. (2025a)](https://link.springer.com/article/10.1007/s11739-025-03888-5)

<a id="heading-3.1.19.5"></a>

##### 3.1.19.5 Treatment

<a id="topic-3.1.19.5-1"></a>

###### Cytisine administration

| Characteristic | Quoted value |
| --- | --- |
| Oral cytisine unit dose | “1.5 mg” |
| Treatment duration | “25 days” |

Source: [Tedesco et al. (2025a)](https://link.springer.com/article/10.1007/s11739-025-03888-5)

<a id="heading-3.1.19.6"></a>

##### 3.1.19.6 Study Outcomes

<a id="heading-3.1.19.6.1"></a>

###### 3.1.19.6.1 Rationale for Using Adverse Drug Reactions as the Primary Safety Endpoint

<a id="topic-3.1.19.6.1-1"></a>

###### Primary outcome

> “The primary endpoint was CYT safety”

Source: [Tedesco et al. (2025a)](https://link.springer.com/article/10.1007/s11739-025-03888-5)

<a id="heading-3.1.19.7"></a>

##### 3.1.19.7 Statistical Analysis Description

<a id="heading-3.1.19.7.1"></a>

###### 3.1.19.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.19.7.1-1"></a>

###### Enrolled participants

| Characteristic | Quoted value |
| --- | --- |
| Cohort size | “36” |

Source: [Tedesco et al. (2025a)](https://link.springer.com/article/10.1007/s11739-025-03888-5)

<a id="heading-3.1.19.7.2"></a>

###### 3.1.19.7.2 Description of Analysis Sets

<a id="topic-3.1.19.7.2-1"></a>

###### Minimum exposure for analysis

> “at least one capsule”

Source: [Tedesco et al. (2025a)](https://link.springer.com/article/10.1007/s11739-025-03888-5)

<a id="heading-3.1.19.8"></a>

##### 3.1.19.8 Results

<a id="heading-3.1.19.8.1"></a>

###### 3.1.19.8.1 Participant Disposition

<a id="topic-3.1.19.8.1-1"></a>

###### Study completion

| Characteristic | Quoted value |
| --- | --- |
| Participants completing the study | “22 (61.1%)” |

Source: [Tedesco et al. (2025a)](https://link.springer.com/article/10.1007/s11739-025-03888-5)

<a id="heading-3.1.19.8.2"></a>

###### 3.1.19.8.2 Baseline Characteristics

<a id="topic-3.1.19.8.2-1"></a>

###### Baseline sex

| Characteristic | Quoted value |
| --- | --- |
| Male participants | “83.3%” |

Source: [Tedesco et al. (2025a)](https://link.springer.com/article/10.1007/s11739-025-03888-5)

<a id="heading-3.1.19.8.3"></a>

###### 3.1.19.8.3 Efficacy Results

<a id="topic-3.1.19.8.3-1"></a>

###### Self-reported seven-day point-prevalence abstinence

| Characteristic | Quoted value |
| --- | --- |
| At 3 months | “50%” |
| At 6 months | “47%” |
| At 12 months | “36%” |

Source: [Tedesco et al. (2025a)](https://link.springer.com/article/10.1007/s11739-025-03888-5)

Additional sources: [Tedesco et al. (2025b)](https://link.springer.com/article/10.1007/s11739-025-04067-2)

<a id="heading-3.1.19.8.4"></a>

###### 3.1.19.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.19.8.5"></a>

###### 3.1.19.8.5 Safety Results

<a id="topic-3.1.19.8.5-1"></a>

###### Primary safety findings

> “The primary endpoint was CYT safety, with 11 mild-moderate Adverse Drug Reactions (ADRs) reported by 9 (25%) participants.”

Source: [Tedesco et al. (2025a)](https://link.springer.com/article/10.1007/s11739-025-03888-5)

<a id="heading-3.1.19.9"></a>

##### 3.1.19.9 Study Limitations

<a id="topic-3.1.19.9-1"></a>

###### Summary

The evidence comes from a prospective observational cohort of 36 hospitalized smokers with cardiovascular disease. Its small size and lack of randomized comparison limit causal interpretation and assessment of uncommon cardiovascular harms. The reported longitudinal cessation percentages are self-reported outcomes.

Source: [Tedesco et al. (2025a)](https://link.springer.com/article/10.1007/s11739-025-03888-5)

<a id="heading-3.1.20"></a>

#### 3.1.20 Retrospective comparative-effectiveness cohort

<a id="heading-3.1.20.1"></a>

##### 3.1.20.1 Objective

<a id="topic-3.1.20.1-1"></a>

###### Clinical objective

> “smoking cessation”

Source: [Bektaş Aksoy (2026)](https://www.tobaccoinduceddiseases.org/Real-world-effectiveness-of-cytisine-bupropion-and-nicotine-nreplacement-therapy%2C217961%2C0%2C2.html)

<a id="heading-3.1.20.2"></a>

##### 3.1.20.2 Location and Study Date

<a id="topic-3.1.20.2-1"></a>

###### Study country

> “Türkiye”

Source: [Bektaş Aksoy (2026)](https://www.tobaccoinduceddiseases.org/Real-world-effectiveness-of-cytisine-bupropion-and-nicotine-nreplacement-therapy%2C217961%2C0%2C2.html)

<a id="heading-3.1.20.3"></a>

##### 3.1.20.3 Study Design

<a id="topic-3.1.20.3-1"></a>

###### Treatment allocation

> “Treatment allocation was based on routine clinical practice rather than randomization.”

Source: [Bektaş Aksoy (2026)](https://www.tobaccoinduceddiseases.org/Real-world-effectiveness-of-cytisine-bupropion-and-nicotine-nreplacement-therapy%2C217961%2C0%2C2.html)

<a id="heading-3.1.20.4"></a>

##### 3.1.20.4 Eligibility Criteria

<a id="topic-3.1.20.4-1"></a>

###### Adult eligibility

| Characteristic | Quoted value |
| --- | --- |
| Minimum age, years | “18” |

Source: [Bektaş Aksoy (2026)](https://www.tobaccoinduceddiseases.org/Real-world-effectiveness-of-cytisine-bupropion-and-nicotine-nreplacement-therapy%2C217961%2C0%2C2.html)

<a id="heading-3.1.20.5"></a>

##### 3.1.20.5 Treatment

<a id="topic-3.1.20.5-1"></a>

###### Medication groups

| Characteristic | Quoted value |
| --- | --- |
| Treatments compared | “cytisine, bupropion, and nicotine replacement therapy” |

Source: [Bektaş Aksoy (2026)](https://www.tobaccoinduceddiseases.org/Real-world-effectiveness-of-cytisine-bupropion-and-nicotine-nreplacement-therapy%2C217961%2C0%2C2.html)

<a id="heading-3.1.20.6"></a>

##### 3.1.20.6 Study Outcomes

<a id="heading-3.1.20.6.1"></a>

###### 3.1.20.6.1 Rationale for Using Self-reported Smoking Abstinence as a Study Endpoint

<a id="topic-3.1.20.6.1-1"></a>

###### Abstinence ascertainment

> “self-reported”

Source: [Bektaş Aksoy (2026)](https://www.tobaccoinduceddiseases.org/Real-world-effectiveness-of-cytisine-bupropion-and-nicotine-nreplacement-therapy%2C217961%2C0%2C2.html)

<a id="heading-3.1.20.7"></a>

##### 3.1.20.7 Statistical Analysis Description

<a id="heading-3.1.20.7.1"></a>

###### 3.1.20.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.20.7.1-1"></a>

###### Analyzed participants

| Characteristic | Quoted value |
| --- | --- |
| Total cohort | “113” |

Source: [Bektaş Aksoy (2026)](https://www.tobaccoinduceddiseases.org/Real-world-effectiveness-of-cytisine-bupropion-and-nicotine-nreplacement-therapy%2C217961%2C0%2C2.html)

<a id="heading-3.1.20.7.2"></a>

###### 3.1.20.7.2 Description of Analysis Sets

<a id="topic-3.1.20.7.2-1"></a>

###### Adjustment limitation

> “multivariable modeling was not performed.”

Source: [Bektaş Aksoy (2026)](https://www.tobaccoinduceddiseases.org/Real-world-effectiveness-of-cytisine-bupropion-and-nicotine-nreplacement-therapy%2C217961%2C0%2C2.html)

<a id="heading-3.1.20.8"></a>

##### 3.1.20.8 Results

<a id="heading-3.1.20.8.1"></a>

###### 3.1.20.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.20.8.2"></a>

###### 3.1.20.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.20.8.3"></a>

###### 3.1.20.8.3 Efficacy Results

<a id="topic-3.1.20.8.3-1"></a>

###### Treatment adherence and outcome

> “Treatment adherence emerged as a key determinant of cessation outcomes.”

Source: [Bektaş Aksoy (2026)](https://www.tobaccoinduceddiseases.org/Real-world-effectiveness-of-cytisine-bupropion-and-nicotine-nreplacement-therapy%2C217961%2C0%2C2.html)

<a id="topic-3.1.20.8.3-2"></a>

###### Overall cessation

| Characteristic | Quoted value |
| --- | --- |
| Participants classified as quitters | “67” |
| Participants classified as non-quitters | “46” |

Source: [Bektaş Aksoy (2026)](https://www.tobaccoinduceddiseases.org/Real-world-effectiveness-of-cytisine-bupropion-and-nicotine-nreplacement-therapy%2C217961%2C0%2C2.html)

<a id="heading-3.1.20.8.4"></a>

###### 3.1.20.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.20.8.5"></a>

###### 3.1.20.8.5 Safety Results

No evidence found.

<a id="heading-3.1.20.9"></a>

##### 3.1.20.9 Study Limitations

<a id="topic-3.1.20.9-1"></a>

###### Summary

Treatment selection reflected routine practice rather than randomization, and multivariable modeling was not performed. The association between adherence and cessation does not establish a causal medication effect or an adjusted comparative treatment effect.

Source: [Bektaş Aksoy (2026)](https://www.tobaccoinduceddiseases.org/Real-world-effectiveness-of-cytisine-bupropion-and-nicotine-nreplacement-therapy%2C217961%2C0%2C2.html)

<a id="heading-3.1.21"></a>

#### 3.1.21 DESTINA

<a id="heading-3.1.21.1"></a>

##### 3.1.21.1 Objective

No evidence found.

<a id="heading-3.1.21.2"></a>

##### 3.1.21.2 Location and Study Date

No evidence found.

<a id="heading-3.1.21.3"></a>

##### 3.1.21.3 Study Design

No evidence found.

<a id="heading-3.1.21.4"></a>

##### 3.1.21.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.21.5"></a>

##### 3.1.21.5 Treatment

No evidence found.

<a id="heading-3.1.21.6"></a>

##### 3.1.21.6 Study Outcomes

<a id="heading-3.1.21.6.1"></a>

###### 3.1.21.6.1 Rationale for Using Patient Satisfaction and Tolerability as the Study Outcomes

No evidence found.

<a id="heading-3.1.21.7"></a>

##### 3.1.21.7 Statistical Analysis Description

<a id="heading-3.1.21.7.1"></a>

###### 3.1.21.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.21.7.2"></a>

###### 3.1.21.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.21.8"></a>

##### 3.1.21.8 Results

<a id="heading-3.1.21.8.1"></a>

###### 3.1.21.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.21.8.2"></a>

###### 3.1.21.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.21.8.3"></a>

###### 3.1.21.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.21.8.4"></a>

###### 3.1.21.8.4 Health-related Quality of Life and Patient-reported Outcomes

Additional sources: [Jiménez-Ruiz et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36549936/)

<a id="heading-3.1.21.8.5"></a>

###### 3.1.21.8.5 Safety Results

No evidence found.

<a id="heading-3.1.21.9"></a>

##### 3.1.21.9 Study Limitations

No evidence found.

<a id="heading-3.1.22"></a>

#### 3.1.22 Placebo-controlled trial in workers

<a id="heading-3.1.22.1"></a>

##### 3.1.22.1 Objective

<a id="topic-3.1.22.1-1"></a>

###### Clinical objective

> “efficacy of cytisine”

Source: [Vinnikov et al. (2008)](https://www.cambridge.org/core/journals/journal-of-smoking-cessation/article/abs/doubleblind-randomised-placebocontrolled-trial-of-cytisine-for-smoking-cessation-in-mediumdependent-workers/FD545EF13935E1F029600D6D1BC8A3DD)

<a id="heading-3.1.22.2"></a>

##### 3.1.22.2 Location and Study Date

No evidence found.

<a id="heading-3.1.22.3"></a>

##### 3.1.22.3 Study Design

<a id="topic-3.1.22.3-1"></a>

###### Blinded randomized design

> “randomized controlled double-blind trial”

Source: [Vinnikov et al. (2008)](https://www.cambridge.org/core/journals/journal-of-smoking-cessation/article/abs/doubleblind-randomised-placebocontrolled-trial-of-cytisine-for-smoking-cessation-in-mediumdependent-workers/FD545EF13935E1F029600D6D1BC8A3DD)

<a id="heading-3.1.22.4"></a>

##### 3.1.22.4 Eligibility Criteria

<a id="topic-3.1.22.4-1"></a>

###### Occupational population

> “mining industry”

Source: [Vinnikov et al. (2008)](https://www.cambridge.org/core/journals/journal-of-smoking-cessation/article/abs/doubleblind-randomised-placebocontrolled-trial-of-cytisine-for-smoking-cessation-in-mediumdependent-workers/FD545EF13935E1F029600D6D1BC8A3DD)

<a id="heading-3.1.22.5"></a>

##### 3.1.22.5 Treatment

<a id="topic-3.1.22.5-1"></a>

###### Treatment course

> “25-days regimen”

Source: [Vinnikov et al. (2008)](https://www.cambridge.org/core/journals/journal-of-smoking-cessation/article/abs/doubleblind-randomised-placebocontrolled-trial-of-cytisine-for-smoking-cessation-in-mediumdependent-workers/FD545EF13935E1F029600D6D1BC8A3DD)

<a id="heading-3.1.22.6"></a>

##### 3.1.22.6 Study Outcomes

<a id="heading-3.1.22.6.1"></a>

###### 3.1.22.6.1 Rationale for Using Self-reported Continuous Abstinence as a Study Endpoint

<a id="topic-3.1.22.6.1-1"></a>

###### Outcome ascertainment

> “Self-reported continuous abstinence”

Source: [Vinnikov et al. (2008)](https://www.cambridge.org/core/journals/journal-of-smoking-cessation/article/abs/doubleblind-randomised-placebocontrolled-trial-of-cytisine-for-smoking-cessation-in-mediumdependent-workers/FD545EF13935E1F029600D6D1BC8A3DD)

<a id="heading-3.1.22.7"></a>

##### 3.1.22.7 Statistical Analysis Description

<a id="heading-3.1.22.7.1"></a>

###### 3.1.22.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.22.7.1-1"></a>

###### Randomized participants

| Characteristic | Quoted value |
| --- | --- |
| Total | “171” |

Source: [Vinnikov et al. (2008)](https://www.cambridge.org/core/journals/journal-of-smoking-cessation/article/abs/doubleblind-randomised-placebocontrolled-trial-of-cytisine-for-smoking-cessation-in-mediumdependent-workers/FD545EF13935E1F029600D6D1BC8A3DD)

<a id="heading-3.1.22.7.2"></a>

###### 3.1.22.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.22.8"></a>

##### 3.1.22.8 Results

<a id="heading-3.1.22.8.1"></a>

###### 3.1.22.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.22.8.2"></a>

###### 3.1.22.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.22.8.3"></a>

###### 3.1.22.8.3 Efficacy Results

<a id="topic-3.1.22.8.3-1"></a>

###### Abstinence at 26 weeks

> “at 26 weeks 10.6% of subjects were abstinent in cytisine group compared to 1.2% in placebo (p = .01).”

Source: [Vinnikov et al. (2008)](https://www.cambridge.org/core/journals/journal-of-smoking-cessation/article/abs/doubleblind-randomised-placebocontrolled-trial-of-cytisine-for-smoking-cessation-in-mediumdependent-workers/FD545EF13935E1F029600D6D1BC8A3DD)

<a id="heading-3.1.22.8.4"></a>

###### 3.1.22.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.22.8.4-1"></a>

###### Quality of life

> “quality of life improved in both groups”

Source: [Vinnikov et al. (2008)](https://www.cambridge.org/core/journals/journal-of-smoking-cessation/article/abs/doubleblind-randomised-placebocontrolled-trial-of-cytisine-for-smoking-cessation-in-mediumdependent-workers/FD545EF13935E1F029600D6D1BC8A3DD)

<a id="heading-3.1.22.8.5"></a>

###### 3.1.22.8.5 Safety Results

No evidence found.

<a id="heading-3.1.22.9"></a>

##### 3.1.22.9 Study Limitations

<a id="topic-3.1.22.9-1"></a>

###### Summary

Abstinence was self-reported. The study enrolled men working in mining, limiting direct applicability to broader clinical populations. It evaluated a 25-day regimen rather than the longer ORCA regimens.

Source: [Vinnikov et al. (2008)](https://www.cambridge.org/core/journals/journal-of-smoking-cessation/article/abs/doubleblind-randomised-placebocontrolled-trial-of-cytisine-for-smoking-cessation-in-mediumdependent-workers/FD545EF13935E1F029600D6D1BC8A3DD); [Rigotti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10336611/)

<a id="heading-3.1.23"></a>

#### 3.1.23 Matching-adjusted indirect comparison

<a id="heading-3.1.23.1"></a>

##### 3.1.23.1 Objective

<a id="topic-3.1.23.1-1"></a>

###### Comparative objective

> “efficacy and safety”

Source: [Rubinstein et al. (2026c)](https://jheor.org/article/160017-comparative-effectiveness-of-cytisinicline-and-varenicline-for-smoking-cessation-a-matching-adjusted-indirect-comparison-maic)

<a id="heading-3.1.23.2"></a>

##### 3.1.23.2 Location and Study Date

Not applicable.

<a id="heading-3.1.23.3"></a>

##### 3.1.23.3 Study Design

<a id="topic-3.1.23.3-1"></a>

###### Indirect comparative design

> “matching-adjusted indirect treatment comparison”

Source: [Rubinstein et al. (2026c)](https://jheor.org/article/160017-comparative-effectiveness-of-cytisinicline-and-varenicline-for-smoking-cessation-a-matching-adjusted-indirect-comparison-maic)

<a id="heading-3.1.23.4"></a>

##### 3.1.23.4 Eligibility Criteria

<a id="topic-3.1.23.4-1"></a>

###### Comparator population

> “nonpsychiatric”

Source: [Rubinstein et al. (2026c)](https://jheor.org/article/160017-comparative-effectiveness-of-cytisinicline-and-varenicline-for-smoking-cessation-a-matching-adjusted-indirect-comparison-maic)

<a id="heading-3.1.23.5"></a>

##### 3.1.23.5 Treatment

<a id="topic-3.1.23.5-1"></a>

###### Treatment exposure

| Characteristic | Quoted value |
| --- | --- |
| Cytisinicline course | “12 weeks” |

Source: [Rubinstein et al. (2026c)](https://jheor.org/article/160017-comparative-effectiveness-of-cytisinicline-and-varenicline-for-smoking-cessation-a-matching-adjusted-indirect-comparison-maic)

<a id="heading-3.1.23.6"></a>

##### 3.1.23.6 Study Outcomes

<a id="heading-3.1.23.6.1"></a>

###### 3.1.23.6.1 Rationale for Using Continuous Smoking Abstinence as the Primary Endpoint

<a id="topic-3.1.23.6.1-1"></a>

###### Abstinence assessment intervals

| Characteristic | Quoted value |
| --- | --- |
| End of treatment | “Weeks 9-12” |
| Longer follow-up | “Weeks 9-24” |

Source: [Rubinstein et al. (2026c)](https://jheor.org/article/160017-comparative-effectiveness-of-cytisinicline-and-varenicline-for-smoking-cessation-a-matching-adjusted-indirect-comparison-maic)

<a id="heading-3.1.23.7"></a>

##### 3.1.23.7 Statistical Analysis Description

<a id="heading-3.1.23.7.1"></a>

###### 3.1.23.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.23.7.1-1"></a>

###### Contributing cytisinicline trials

| Characteristic | Quoted value |
| --- | --- |
| Trials pooled | “ORCA-2 and ORCA-3” |

Source: [Rubinstein et al. (2026c)](https://jheor.org/article/160017-comparative-effectiveness-of-cytisinicline-and-varenicline-for-smoking-cessation-a-matching-adjusted-indirect-comparison-maic)

<a id="heading-3.1.23.7.2"></a>

###### 3.1.23.7.2 Description of Analysis Sets

<a id="topic-3.1.23.7.2-1"></a>

###### Adjustment approach

> “propensity score weighting”

Source: [Rubinstein et al. (2026c)](https://jheor.org/article/160017-comparative-effectiveness-of-cytisinicline-and-varenicline-for-smoking-cessation-a-matching-adjusted-indirect-comparison-maic)

<a id="heading-3.1.23.8"></a>

##### 3.1.23.8 Results

<a id="heading-3.1.23.8.1"></a>

###### 3.1.23.8.1 Participant Disposition

Not applicable.

<a id="heading-3.1.23.8.2"></a>

###### 3.1.23.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.23.8.3"></a>

###### 3.1.23.8.3 Efficacy Results

<a id="topic-3.1.23.8.3-1"></a>

###### Adjusted continuous-abstinence estimates

| Assessment                        | Quoted estimate                        |
| --------------------------------- | -------------------------------------- |
| Continuous abstinence, weeks 9–12 | “adjusted OR, 1.33; 95% CI, 0.86-2.05” |
| Continuous abstinence, weeks 9–24 | “adjusted OR, 1.95; 95% CI, 1.13-3.34” |

Source: [Rubinstein et al. (2026c)](https://jheor.org/article/160017-comparative-effectiveness-of-cytisinicline-and-varenicline-for-smoking-cessation-a-matching-adjusted-indirect-comparison-maic)

<a id="heading-3.1.23.8.4"></a>

###### 3.1.23.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.23.8.5"></a>

###### 3.1.23.8.5 Safety Results

<a id="topic-3.1.23.8.5-1"></a>

###### Adjusted nausea estimate

| Assessment                        | Quoted estimate                        |
| --------------------------------- | -------------------------------------- |
| Nausea                            | “adjusted OR, 0.18; 95% CI, 0.10-0.31” |

Source: [Rubinstein et al. (2026c)](https://jheor.org/article/160017-comparative-effectiveness-of-cytisinicline-and-varenicline-for-smoking-cessation-a-matching-adjusted-indirect-comparison-maic)

<a id="heading-3.1.23.9"></a>

##### 3.1.23.9 Study Limitations

<a id="topic-3.1.23.9-1"></a>

###### Summary

This is an indirect comparison, not a randomized head-to-head trial. Weighting cannot remove confounding from unmeasured differences between trials. The weeks 9–12 odds-ratio confidence interval includes no difference, while the weeks 9–24 interval does not. These estimates should not be interpreted as head-to-head evidence.

Source: [Rubinstein et al. (2026c)](https://jheor.org/article/160017-comparative-effectiveness-of-cytisinicline-and-varenicline-for-smoking-cessation-a-matching-adjusted-indirect-comparison-maic); [Rubinstein et al. (2026d)](https://achievelifesciences.com/wp-content/uploads/2026/05/ATS_2026_MAIC.pdf)

<a id="topic-3.1.23.9-2"></a>

###### Residual confounding

> “As with all indirect comparisons, results may be influenced by residual confounding due to unmeasured differences between trials”

Source: [Rubinstein et al. (2026d)](https://achievelifesciences.com/wp-content/uploads/2026/05/ATS_2026_MAIC.pdf)

<a id="heading-3.1.24"></a>

#### 3.1.24 Phase I dose-escalation study

<a id="heading-3.1.24.1"></a>

##### 3.1.24.1 Objective

No evidence found.

<a id="heading-3.1.24.2"></a>

##### 3.1.24.2 Location and Study Date

No evidence found.

<a id="heading-3.1.24.3"></a>

##### 3.1.24.3 Study Design

No evidence found.

<a id="heading-3.1.24.4"></a>

##### 3.1.24.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.24.5"></a>

##### 3.1.24.5 Treatment

No evidence found.

<a id="heading-3.1.24.6"></a>

##### 3.1.24.6 Study Outcomes

<a id="heading-3.1.24.6.1"></a>

###### 3.1.24.6.1 Rationale for Using Tolerability and Safety as the Primary Endpoints

No evidence found.

<a id="heading-3.1.24.7"></a>

##### 3.1.24.7 Statistical Analysis Description

<a id="heading-3.1.24.7.1"></a>

###### 3.1.24.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.24.7.2"></a>

###### 3.1.24.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.24.8"></a>

##### 3.1.24.8 Results

<a id="heading-3.1.24.8.1"></a>

###### 3.1.24.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.24.8.2"></a>

###### 3.1.24.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.24.8.3"></a>

###### 3.1.24.8.3 Efficacy Results

Not applicable.

<a id="heading-3.1.24.8.4"></a>

###### 3.1.24.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.24.8.5"></a>

###### 3.1.24.8.5 Safety Results

Additional sources: [Jacobs et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36198104/)

<a id="heading-3.1.24.9"></a>

##### 3.1.24.9 Study Limitations

No evidence found.

<a id="heading-3.1.25"></a>

#### 3.1.25 Single-dose pharmacokinetic study

<a id="heading-3.1.25.1"></a>

##### 3.1.25.1 Objective

<a id="topic-3.1.25.1-1"></a>

###### Pharmacokinetic objective

> “pharmacokinetics of cytisine”

Source: [Jeong et al. (2015)](https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.1707)

<a id="heading-3.1.25.2"></a>

##### 3.1.25.2 Location and Study Date

No evidence found.

<a id="heading-3.1.25.3"></a>

##### 3.1.25.3 Study Design

<a id="topic-3.1.25.3-1"></a>

###### Exposure design

> “Single-dose pharmacokinetics”

Source: [Jeong et al. (2015)](https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.1707)

<a id="heading-3.1.25.4"></a>

##### 3.1.25.4 Eligibility Criteria

<a id="topic-3.1.25.4-1"></a>

###### Population

> “healthy smokers”

Source: [Jeong et al. (2015)](https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.1707)

<a id="heading-3.1.25.5"></a>

##### 3.1.25.5 Treatment

<a id="topic-3.1.25.5-1"></a>

###### Oral dose

> “3 mg”

Source: [Jeong et al. (2015)](https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.1707)

<a id="heading-3.1.25.6"></a>

##### 3.1.25.6 Study Outcomes

<a id="heading-3.1.25.6.1"></a>

###### 3.1.25.6.1 Rationale for Using Plasma and Urinary Cytisine Concentrations as the Pharmacokinetic Endpoints

Not applicable.

<a id="heading-3.1.25.7"></a>

##### 3.1.25.7 Statistical Analysis Description

<a id="heading-3.1.25.7.1"></a>

###### 3.1.25.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.25.7.2"></a>

###### 3.1.25.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.25.8"></a>

##### 3.1.25.8 Results

<a id="heading-3.1.25.8.1"></a>

###### 3.1.25.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.25.8.2"></a>

###### 3.1.25.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.25.8.3"></a>

###### 3.1.25.8.3 Efficacy Results

<a id="topic-3.1.25.8.3-1"></a>

###### Pharmacokinetic elimination findings

> “Cytisine was renally excreted and detected as an unchanged drug. No metabolites were detected in plasma or urine collected in the study.”

Source: [Jeong et al. (2015)](https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.1707)

<a id="heading-3.1.25.8.4"></a>

###### 3.1.25.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.25.8.5"></a>

###### 3.1.25.8.5 Safety Results

<a id="topic-3.1.25.8.5-1"></a>

###### Adverse reactions

> “No adverse reactions were reported.”

Source: [Jeong et al. (2015)](https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.1707)

<a id="heading-3.1.25.9"></a>

##### 3.1.25.9 Study Limitations

<a id="topic-3.1.25.9-1"></a>

###### Summary

The study characterized a single dose in healthy smokers. It does not establish smoking-cessation efficacy or the safety of repeated administration for 6 or 12 weeks.

Source: [Jeong et al. (2015)](https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.1707); [Rigotti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10336611/)

<a id="heading-3.1.26"></a>

#### 3.1.26 ACTRN12613000002785

<a id="heading-3.1.26.1"></a>

##### 3.1.26.1 Objective

<a id="topic-3.1.26.1-1"></a>

###### Exposure objective

> “plasma concentrations”

Source: [Jeong et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29168931/)

<a id="heading-3.1.26.2"></a>

##### 3.1.26.2 Location and Study Date

No evidence found.

<a id="heading-3.1.26.3"></a>

##### 3.1.26.3 Study Design

<a id="topic-3.1.26.3-1"></a>

###### Repeated-dose regimen

> “25-day standard dosing regimen”

Source: [Jeong et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29168931/)

<a id="heading-3.1.26.4"></a>

##### 3.1.26.4 Eligibility Criteria

<a id="topic-3.1.26.4-1"></a>

###### Population

> “healthy adult smokers”

Source: [Jeong et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29168931/)

<a id="heading-3.1.26.5"></a>

##### 3.1.26.5 Treatment

<a id="topic-3.1.26.5-1"></a>

###### Regimen duration

| Characteristic | Quoted value |
| --- | --- |
| Treatment period | “25-day” |

Source: [Jeong et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29168931/)

<a id="heading-3.1.26.6"></a>

##### 3.1.26.6 Study Outcomes

<a id="heading-3.1.26.6.1"></a>

###### 3.1.26.6.1 Rationale for Using Plasma Cytisine Concentrations as the Pharmacokinetic Endpoint

Not applicable.

<a id="heading-3.1.26.7"></a>

##### 3.1.26.7 Statistical Analysis Description

<a id="heading-3.1.26.7.1"></a>

###### 3.1.26.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.26.7.1-1"></a>

###### Participants

| Characteristic | Quoted value |
| --- | --- |
| Study sample | “10” |

Source: [Jeong et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29168931/)

<a id="heading-3.1.26.7.2"></a>

###### 3.1.26.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.26.8"></a>

##### 3.1.26.8 Results

<a id="heading-3.1.26.8.1"></a>

###### 3.1.26.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.26.8.2"></a>

###### 3.1.26.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.26.8.3"></a>

###### 3.1.26.8.3 Efficacy Results

<a id="topic-3.1.26.8.3-1"></a>

###### Accumulation after repeated dosing

> “Accumulation of cytisine was observed with repeated dosing of cytisine on day 1.”

Source: [Jeong et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29168931/)

<a id="heading-3.1.26.8.4"></a>

###### 3.1.26.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.26.8.5"></a>

###### 3.1.26.8.5 Safety Results

<a id="topic-3.1.26.8.5-1"></a>

###### Reported adverse effects

> “adverse effects reported were minor”

Source: [Jeong et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29168931/)

<a id="heading-3.1.26.9"></a>

##### 3.1.26.9 Study Limitations

<a id="topic-3.1.26.9-1"></a>

###### Summary

The pharmacokinetic study included 10 healthy adult smokers and used the standard 25-day regimen. It provides evidence of accumulation but cannot establish clinical cessation efficacy or detect uncommon harms.

Source: [Jeong et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29168931/)

<a id="heading-3.1.27"></a>

#### 3.1.27 Ascending-dose pharmacokinetic study

<a id="heading-3.1.27.1"></a>

##### 3.1.27.1 Objective

No evidence found.

<a id="heading-3.1.27.2"></a>

##### 3.1.27.2 Location and Study Date

No evidence found.

<a id="heading-3.1.27.3"></a>

##### 3.1.27.3 Study Design

No evidence found.

<a id="heading-3.1.27.4"></a>

##### 3.1.27.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.27.5"></a>

##### 3.1.27.5 Treatment

No evidence found.

<a id="heading-3.1.27.6"></a>

##### 3.1.27.6 Study Outcomes

<a id="heading-3.1.27.6.1"></a>

###### 3.1.27.6.1 Rationale for Using Cytisine Pharmacokinetics as the Primary Endpoint

Not applicable.

<a id="heading-3.1.27.7"></a>

##### 3.1.27.7 Statistical Analysis Description

<a id="heading-3.1.27.7.1"></a>

###### 3.1.27.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.27.7.2"></a>

###### 3.1.27.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.27.8"></a>

##### 3.1.27.8 Results

<a id="heading-3.1.27.8.1"></a>

###### 3.1.27.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.27.8.2"></a>

###### 3.1.27.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.27.8.3"></a>

###### 3.1.27.8.3 Efficacy Results

Not applicable.

<a id="heading-3.1.27.8.4"></a>

###### 3.1.27.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.27.8.5"></a>

###### 3.1.27.8.5 Safety Results

No evidence found.

<a id="heading-3.1.27.9"></a>

##### 3.1.27.9 Study Limitations

No evidence found.

## Related pages
- [Cytisinicline: Smoking cessation](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation.md)
- [Cytisinicline in Smoking cessation: Terms and abbreviations](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/terms-and-abbreviations.md)
- [Cytisinicline: Smoking cessation](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/executive-summary.md)
- [Cytisinicline in Smoking cessation: Product information and disease description](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/product-information-and-disease-description.md)
- [Cytisinicline in Smoking cessation: Economic information and modeling report](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/economics) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/economics.md)
- [Cytisinicline in Smoking cessation: References](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/references) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/references.md)
- [Cytisinicline in Smoking cessation: prevalence by geography](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/prevalence) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/prevalence.md)
- [Cytisinicline in Smoking cessation: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/cost-effectiveness-analyses.md)
